Rti surgical, inc.(rti) and tutogen medical (b)(4), a wholly owned subsidiary of rti received a complaint on (b)(6) 2014 reporting that a patient underwent a difficult small bowel repair, a contaminated wound site, with abdominal wall reconstruction utilizing a fortiva graft on (b)(6) 2014.The patient was readmitted on (b)(6) 2014 due to the development of wound dehiscence with graft degradation noted.Medical records were requested but not received.
|
Method: graft was not returned to rti for evaluation, therefore, a re-review was performed of the manufacturing records, sterilization run reports, environmental monitoring results, quality control/assurance reviews and release, and the complaint database for related complaints associated with the lot.Results: no deviations were noted during the records re-review for lot# mp130701.The graft underwent a validated sterilization; tutoplast which includes terminal sterilization by gama irradiation after packaging.To date, rti has distributed (b)(4) xenografts from the lot and distributed (b)(4) without related complaints.Environmental data and records generated during and around the time of processing for lot# mp130701 were acceptable.Conclusion: given that (1) no deviations were noted in records re-review, graft id (b)(6) manufactured to specification prior to distribution, and (2) per physician report in the complaint notification, the graft was utilized in a contaminated wound site, it is more plausible that the patient's outcome and complications were associated with a source or event extrinsic to the xenograft implant.
|